<DOC>
	<DOCNO>NCT01947439</DOCNO>
	<brief_summary>The risk restenosis treatment coronary artery disease significantly lessen thanks introduction Drug elute stent . Yet , debate efficacy safety stent complex lesion patient circulate . Recently , PCI multiple lesion universally perform development effective stent various kind clinic . However , randomize study rare multi-vessel coronary artery disease real procedural environment . The primary purpose study evaluate clinical progress biolimus A9-eluting stent zotarolimus-eluting stent multi-vessel coronary artery disease .</brief_summary>
	<brief_title>Comparison Biolimus A9-eluting Stent With Zotarolimus -Eluting Stent Multi-vessel PCI</brief_title>
	<detailed_description>The patient need multi-vessel stenting multi-vessel coronary artery disease enrolled.Each randomization enrol subject do 1:1 ( biolimus A9-eluting stent : zotarolimus-eluting stent ) . Randomization stratify two factor : Diabetes mellitus Acute coronary syndrome.Clinical follow-up occur follow time point ; 1 month , 1 year 2 year .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>patient need multivessel stenting multivessel disease patient sign informed consent know contraindication follow medication : Aspirin , clopidogrel , heparin , contrast agent , Biolimus Zotarolimus group Cardiogenic shock Pregnant woman woman potential childbearing Endstage diseases life expectancy short 2 year patient Drug elute stent implanted Patients require modification antiplatelet agent plan major surgery within first 12 month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>multivessel stenting</keyword>
</DOC>